NewsRoom Articles - Page 74 of 154 - PsychedelicNewsWire (PNW)

ThursdayDec 30, 2021 1:19 pm

Psychedelics May Be Key to Effective Dementia Treatment

Dementia is known to affect an individual’s mental processes, leading to loss of cognitive functioning. It is typically caused by brain injury or disease and is marked by impaired reasoning, changes in personality and memory disorders. In its later stages, the disease kills off the brain cells linked to muscle control, gradually limiting the person’s ability to stand, walk and even swallow food. Estimates from the CDC show that more than 5.7 million individuals suffer from dementia and Alzheimer’s disease, a progressive disorder that destroys memory. Projections show that this number could reach roughly 14 million in the next four…

WednesdayDec 29, 2021 12:33 pm

Congressman Calls on Colleagues to Urge DEA to Permit Psilocybin Access

Rep. Earl Blumenauer is asking fellow legislators to join him in urging the DEA to permit patients suffering from terminal illnesses to use psilocybin as part of their treatment, without fear of being federally prosecuted. In a letter circulated by Blumenauer, he notes that there are federal as well as state right-to-try legislations that should allow particular patients to access the psychedelic as an investigational treatment. Blumenauer states in the letter that there existed a growing body of evidence pointing to the effectiveness and safety of psilocybin-assisted therapy as a possible way to provide care to people with anxiety and/or…

WednesdayDec 29, 2021 11:41 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) to Open 2 New Ketamine Infusion Clinics; Co-Founder and CEO Matt Stang Reveals Investor Relations Efforts

Delic Holdings subsidiary, Ketamine Wellness Centers, announced plans to open two new clinics in the coming weeks The clinics, to be located in Salt Lake City, Utah and Reno, Nevada will take KWC’s total clinic count to 14, forming part of the company’s plan to open 13 new ketamine infusion clinics across the country over the next 18 months Following Delic’s keynote ‘Meet Delic’ conference on Nov. 6-7, CEO Matt Stang announced plans to attend the upcoming HC Wainwright Bioconnect Virtual Conference as well as CEM’s 8th annual AlphaNorth Capital Conference in January 2022 Delic Holdings (CSE: DELC) (OTCQB: DELCF),…

TuesdayDec 28, 2021 2:17 pm

New Trial to Test Psilocybin Effectiveness in Treating Depressed Healthcare Workers

Researchers from the School of Medicine at the University of Washington are conducting a clinical trial to treat depressed medical professionals using psychedelics. This comes at a time when healthcare professionals in the United States are seeking ways to deal with the emotional and mental anguish brought on by the coronavirus pandemic. A survey conducted last year that involved more than 20,000 health care workers found that 49% suffered from burnout as a result of the pandemic while another 38% revealed that they had experienced depression or anxiety. Another report from Morning Consult has also highlighted that more than one-half…

MondayDec 27, 2021 2:20 pm

Colorado Activists File Measures to Legalize Psychedelic Substances

Voters in the state of Colorado may get the chance to vote to legalize the growing and possession of psychedelic substances next year, as well as establish a system of licensed businesses to produce psychedelics such as ibogaine, DMT and psilocybin to be used at healing centers. This comes after New Approach PAC filed a pair of psychedelic reform measures for the state’s 2022 ballot with the secretary of state’s office. New Approach PAC is a national advocacy group that is behind the medical psilocybin legalization measure that voters in Oregon passed in 2020, as well as a couple of…

ThursdayDec 23, 2021 1:53 pm

Study Links Ayahuasca’s Ceremonial Use to Decline in Neuroticism

A new study has found evidence suggesting that the use of ayahuasca in ceremonies can cause a substantial decrease in neuroticism. Neuroticism is a personality trait that has been linked to anxiety and depression. Ayahuasca, on the other hand, is a brew that has been used by the indigenous peoples of the Amazonian basin and Brazil for centuries. It contains monoamine oxidase inhibitors and DMT, a potent psychedelic substance. Prior studies have discovered evidence proposing that the consumption of ayahuasca has psychological benefits. Brandon Weiss, an Imperial College London research associate and author of the new study, stated that the…

WednesdayDec 22, 2021 1:16 pm

Study Finds Psychedelic Substances Improve Mental Health by Increasing Emotion Regulation

Findings from a new study show that the use of psychedelics may improve an individual’s mental health. The research, which was published in the “Journal of Humanistic Psychology,” discovered evidence of a pathway that facilitates the increase of spirituality after using psychedelics, which in turn causes better emotion regulation. It is this improvement in emotion regulation that researchers believe decreases disordered eating and symptoms of anxiety and depression. For centuries now, various indigenous tribes of the Amazon as well as other non-Western cultures have used psychedelic substances, including ayahuasca and psilocybin, in spiritual ceremonies. Their medicinal benefits are currently being…

TuesdayDec 21, 2021 3:17 pm

Survey Finds That People Microdosed on Psychedelics to Cope with Pandemic

A recently conducted survey has discovered that during the coronavirus pandemic, individuals who use drugs recreationally have been microdosing on psychedelic substances to improve their mental health. Researchers believe that this discovery shows that some individuals living with mental health conditions obtained relief from microdosing on substances such as psilocybin mushrooms and LSD. The survey was conducted by the Global Drug Survey, an independent research company based in London. From December 2020 to March 2021, the company gathered data from more than 32,000 individuals in 20 countries. The survey found that the majority of the respondents who had used psychedelics…

MondayDec 20, 2021 3:42 pm

DEA in Favor of White House Proposal to Streamline Research on Schedule I Substances

The National Institute on Drug Abuse and the Drug Enforcement Administration (“DEA”) are supporting a new White House plan that would streamline the process of studying substances classified under Schedule I, including cannabis and psychedelics such as psilocybin and LSD. During a House Energy and Commerce subcommittee hearing held earlier this month, the agencies declared their support for the research proposal. The proposal, dubbed the Office of National Drug Control Policy research plan, would also address concerns in the scientific community, including the challenges researchers face when trying to study Schedule I substances. In its written testimony, the DEA stated…

MondayDec 20, 2021 11:53 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), an Undervalued Opportunity for Investment

Mydecine’s and CMPS’ stocks have been grossly undervalued largely due to a lack of understanding of the psychedelic space The situation presents a unique opportunity for investment, as Roth Capital Partners issued a $3 buy rating for 2022 Mydecine has put systems and infrastructure in place to bank on the growing PTSD treatment, smoking cessation, and the health and wellness apps market, in its drive to increase value for its shareholders There has been a huge misunderstanding of the psychedelic space and the potential that this industry has, specifically regarding the treatment of Post-Traumatic Stress Disorder (“PTSD”) and smoking cessation.…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000